Clinical Trials Directory

Trials / Completed

CompletedNCT07328113

Interleukin-6 and Thyroid Dysfunction in Hemodialysis Patients

Association Between Interleukin-6 and Thyroid Hormone Dysfunction in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Status
Completed
Phase
Study type
Observational
Enrollment
65 (actual)
Sponsor
Dr. Soetomo General Hospital · Other Government
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

Chronic kidney disease (CKD) is often associated with multiorgan complications, including thyroid hormone dysfunction. Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been proposed as a marker of inflammation that may contribute to these alterations. The main question it aims to answer is: Is there an association between interleukin-6 and thyroid hormone dysfunction in patients with chronic kidney disease (CKD) Blood samples will be collected and analyzed from 65 patients who have undergone hemodialysis for at least 3 months.

Detailed description

This cross-sectional observational study involves patients with CKD undergoing hemodialysis at Airlangga University Hospital. Data were collected based on their medical record and Blood test for IL-6. Linear regression analysis assessed the relationship between IL-6 levels and thyroid function parameters.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTThyroid hormoneSampling was carried out using a consecutive sampling method, in which every patient who met the study criteria was included as a sample until the predetermined sample size was achieved. Patients who had been confirmed to meet the inclusion and exclusion criteria underwent blood collection of 10 mL (serum or plasma) prior to hemodialysis for the examination of complete blood count, BUN, creatinine, albumin, fasting blood glucose, IL-6, FT4, T3, FT3, T4, and TSH. The IL-6 level was measured using the Automatic Immunoassay Fluorescence method with the Automatic Fluorescence Immunoassay Analyzer Vazyme QD-S2000. Thyroid function tests (FT4, T3, T4, FT3, and TSH) were performed using the Enzyme-Linked Immunosorbent Assay (ELISA) method with Autobio Immunoassay reagents on the Autobio A1000 analyzer.

Timeline

Start date
2023-11-14
Primary completion
2024-03-31
Completion
2024-06-30
First posted
2026-01-08
Last updated
2026-01-08

Locations

1 site across 1 country: Indonesia

Source: ClinicalTrials.gov record NCT07328113. Inclusion in this directory is not an endorsement.